web analytics
1.3 C
Munich
Sunday, November 27, 2022

BioElectronics Corp. (OTCPINK: BIEL) Getting Noticed Fast as Biotech Inks New Orders, Initiates New Studies and its RecoveryRx, ActiPatch Gain Traction

BioElectronics Corp. (OTCPINK: BIEL) is sitting right over its 52-week lows of triple 09 coiled tight like a spring and penny stock speculators are accumulating. The stock has a long, long history of making big moves off current levels, the last one which we reported on topped out at $0.0044 in February of last year. BIEL has got the attentions of legions of new shareholders and some big players in small caps who have jumped on board.  The stock has liquidity, plenty of new eyes and volume has been building. Currently under heavy accumulation BIEL is looking to blaze a path into a whole new stratosphere like so many penny stocks did last year – investors are looking for a blue-sky breakout over $0.044. 

BIEL has been busy recently signing two additional international distribution partners and received a new order from its longtime distribution partner in Bangladesh, Multiple Health Pharma, Ltd., who has resumed operations following shutdowns.  These two new international orders and the renewal order total in excess of $200,000.00. BioElectronics has also initiated 3 new studies under the overall supervision of Drs. Ken Mcleod and Richard Staelin including a Stanford Medical Center study on carpal-metacarpal joint osteoarthritis (thumb arthritics), an RCT study in the UK on 70 dogs with the goal of reducing the animals’ arthritis pain and increasing functionality and a third study is currently being conducted by researchers at a major surgical center that specializes in total knee (TKA) replacement. BioElectronics is also in discussions with three other research teams, two interested in studying wound care and the third studying pain reduction. This third study, which is out of the University of California, San Diego medical center, is already in the pilot stage and is looking at refractory phantom pain and total hip and knee pain.   

BioElectronics Corp. (OTCPINK: BIEL) operating out of Frederick, Maryland is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. The Company’s innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications. BIEL sales have increased rapidly; for the 3 months ended September 30, 2021 the Company reported $414,667 in revenues compared to $155,818 for the same period last year. For the 9 months ended September 30, 2021 BIEL reported $1,427,222 in revenues compared to $665,039 for the same period last year.

In February 2017, BioElectronics announced that it received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee. On July 1, 2019 the Company announced that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain. In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch® medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle. 

The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy. 

To Find out the inside Scoop on BIEL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BIEL

BioElectronics recently signed two international distribution partners and received a new order from its longtime distribution partner in Bangladesh, Multiple Health Pharma, Ltd., who has resumed operations following shutdowns due to Covid.  These two new international orders and the renewal order total in excess of $200,000.00. The first new order comes from Stada MENA DWC-LLC. It will be distributing ActiPatch in Bahrain and the Kingdom of Saudi Arabia. Ms. Sanders has also finalized a contract with Modern Development Medical Company., which will be distributing both RecoveryRx and ActiPatch in Kuwait, Qatar, and Oman.  In the United Arab Emirates, they will be focusing on the RecoveryRx brand.   

BioElectronics has been in expansion mode recently hiring on Ms. Zoya Atiq as a Medical Device Compliance Engineer. In her most recent position, she spearheaded a traditional PreMarket Notification 510(k) submission to the FDA for a novel gastrointestinal tube. In her role at BioElectronics, Zoya will be primarily responsible for maintaining the Company’s regulatory/quality compliance with medical device industry standards and regulations. (ie ISO-13485, MDSAP, FDA QSR, 14971). The Company also recently promoted Iqra “Ikki” Anwar-Dean to Director of Operations. In her new role, Ikki will oversee all product production schedules, manage the inventory, and ensure that orders are filled and shipped expeditiously in addition to assisting with marketing.   

In keeping with its emphasis on enhancing the Company’s core capability in PWST technology, BioElectronics has initiated three (3) new studies under the overall supervision of Drs. Ken Mcleod and Richard Staelin.   

  1. The first is with a research group out of Stanford Medical Center which is studying carpal-metacarpal joint osteoarthritis (thumb arthritics) using BioElectronics medical device. This 4-week study is using a randomized control trial (RCT) design on 120 patients. Publication of the results are planned after completion of the trial.
  2. A second RCT study is being conducted in the United Kingdom on 70 dogs with the goal of reducing the animals’ arthritis pain and increasing functionality. The study is ongoing and should be completed in the next few months. In addition to a new application and potential market for BioElectronics device, the Company is also exploring a modified design of the product that has the potential to increase the power of the magnetic field deeper into the body. This study is part of the investigator’s PhD thesis. 
  3. A third study is currently being conducted by researchers at a major surgical center that specializes in total knee (TKA) replacement. This retrospective study design compares 180 TKA patients who used BioElectronics medical device with a matched sample who did not. The primary measures are narcotic use, functionality, and the advent of chronic pain after 90 days. The final draft of the paper is planned for mid-summer of 2022. 

BioElectronics is currently in discussions with three other research teams, two interested in studying wound care and the third studying pain reduction. This third study, which is out of the University of California, San Diego medical center, is already in the pilot stage and is looking at refractory phantom pain and total hip and knee pain.  Such studies will continue to facilitate the Company’s goal of finding new applications and markets for its PSwT technology by highlighting the efficacy and safety of these applications via high quality studies that can be published in peer review medical journals.  

For More on BIEL Subscribe Right Now!

BIEL is sitting right over its 52-week lows of triple 09 coiled tight like a spring and penny stock speculators are accumulating. The stock has a long, long history of making big moves off current levels, the last one which we reported on topped out at $0.0044 in February of last year. BIEL has got the attentions of legions of new shareholders and some big players in small caps who have jumped on board.  The stock has liquidity, plenty of new eyes and volume has been building. Currently under heavy accumulation BIEL is looking to blaze a path into a whole new stratosphere like so many penny stocks did last year – investors are looking for a blue-sky breakout over $0.044. BIEL has been busy recently signing two additional international distribution partners and received a new order from its longtime distribution partner in Bangladesh, Multiple Health Pharma, Ltd., who has resumed operations following shutdowns.  These two new international orders and the renewal order total in excess of $200,000.00. BioElectronics has also initiated 3 new studies under the overall supervision of Drs. Ken Mcleod and Richard Staelin including a Stanford Medical Center study on carpal-metacarpal joint osteoarthritis (thumb arthritics), an RCT study in the UK on 70 dogs with the goal of reducing the animals’ arthritis pain and increasing functionality and a third study is currently being conducted by researchers at a major surgical center that specializes in total knee (TKA) replacement. BioElectronics is also in discussions with three other research teams, two interested in studying wound care and the third studying pain reduction. This third study, which is out of the University of California, San Diego medical center, is already in the pilot stage and is looking at refractory phantom pain and total hip and knee pain. We will be updating on BIEL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in  BIEL either long or short and we have not been compensated for this article

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.